Big pharma, Biotech, M&A, Pharma

Johnson & Johnson has acquired Alios BioPharma

Posted on 01 October 2014

Tags: , ,

Johnson & Johnson announced that it has officially acquired Alios BioPharma for $1.7 billion in cash.

The acquisition will come with Alios’ portfolio of potential therapeutics for viral infections, including AL-8176, an orally administered antiviral therapy currently in Phase 2 studies for the treatment of respiratory syncytial virus.

The closing of the deal is subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act, but it is projected to close by the end of the fourth quarter of 2014.

For further deal information visit Current Agreements (subscription required)

Related

Read: more on M&A deals in pharma, biotech, life science partnering deal news, insights and glossary

Report: Pharma and Biotech M&A Trends 2009-2014

Browse: Complete Current Partnering report catalog

View: M&A Scorecard in CP Insight– view top life science partnering deals by value

View: DealMetrics in CP Insight – the latest deal trend infographics for life science deal making

View: CP Insight’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

View: CP Insight’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter – reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter

Print Friendly, PDF & Email

Leave a Reply

 

cpbannerad300x150new2gif
rauconbadgejpg
e80banner300x150animgif
cabannerad300x150new4gif
rauconbadgejpg
a1banner300x150animgif